Merck Articles
Stock Commentary - Europe - week to Oct 29, 2007
5 November 2007
Merck & Co's OTC Mevacor to go before FDA in Dec
5 November 2007
France
5 November 2007
Dr Reddy's fiscal 2nd-qtr profits fall 4.5%
5 November 2007
NicOx' 9-month 2007 revenue grows 175%
5 November 2007
UK govt announces HPV vaccine timetable
5 November 2007
Merck & Co discontinues HIV vacc trial
29 October 2007
Stock Commentary - New York week to October 22, 2007
29 October 2007
Stock Commentary - Europe - week to October 22, 2007
29 October 2007
Merck & Co's 3rd-qtr 2007 sales jump 12%
29 October 2007
Merck KGaA's net falls but beats forecasts
29 October 2007
CHMP recommends approval of Atripla for HIV-1
29 October 2007
S-P's 3rd-qtr 2007 net income surges 149%
29 October 2007
Iroko buys Canadian antibiotic rights
22 October 2007
sNDA for Merck & Co's Januvia OKed
22 October 2007
Erbitux partners plan for Japan marketing
22 October 2007
AHF attacks another US firm for HIV drug price
22 October 2007
Alemtuzumab cuts relapse risk in RRMS
22 October 2007
Generic HPV vacc could cost under $15 per dose
22 October 2007
Impact of FDA OK for Merck & Co's Isentress
22 October 2007
Gardasil recommended in EU countries
22 October 2007
SMC approves Januvia for type 2 diabetes
22 October 2007
Stock Commentary - Europe - week to Oct 8, 2007
15 October 2007
Merck KGaA
15 October 2007
Pfizer announces management changes
15 October 2007
Global HIV Vaccine Enterprise expands
15 October 2007
Singulair reduces child asthma doctor visits
15 October 2007
Study shows benefits of HPV 6 and 11 vacc
15 October 2007
Management changes at Mylan
8 October 2007
Banyu Pharmaceutical announces David Anstice as president
8 October 2007
Stock Commentary - New York - week to Oct 1, 2007
8 October 2007
Stock Commentary - Europe - week to Oct 1, 2007
8 October 2007
Merck KGaA replaces 2B-euro revolving credit
8 October 2007
Japan stock market week to October 1, 2007
8 October 2007
14th annual ECCO conference hears exciting data on combination therapy with biologics
8 October 2007
SkyePharma's Zyflo CR debuts in USA
8 October 2007
Prix Galien for Abbott's Humira
8 October 2007
Europe leads surge in Pharma M&A deal values
1 October 2007
CHMP gives Merck Serono's Cyanokit thumbs up
1 October 2007
EMEA clears GSK's Cervarix vaccine
1 October 2007
Isentress plus OBT sustains HIV suppression
1 October 2007
Merck & Co's Cancidas comparable to AmBisome in IFI
1 October 2007
Sequel Pharma raises $20M financing
27 September 2007
Prix Galien for Merck & Co's Gardasil and Januvia
27 September 2007
Syvlie Gregoire named president of Shire's Human Genetic Therapies unit
27 September 2007
Stock Commentary - Europe - week to September 24, 2007
27 September 2007
Alnylam terminates deal with Merck & Co
24 September 2007
Stock Commentary - Europe - week to Sept 17, 2007
24 September 2007
Strong data for Merck & Co's sitagliptin plus metformin
24 September 2007
Merck KGaA gets ready to make acquisitions
24 September 2007
BioMarin grants exclusive data on Kuvan to Asubio
24 September 2007
BioXell's six-month loss improves 8%
24 September 2007
UK's NICE says Ezetrol is cost-effective
24 September 2007
AHF blames drug firms for slow ARV uptake
24 September 2007
Small number of combination drugs reaching the Japanese market
24 September 2007
Merck & Co acquires NovaCardia for $366M
17 September 2007
Stock Commentary - New York week to Sept 10, 2007
17 September 2007
Merck & Co to surpass Pfizer in cholesterol-lowering market
17 September 2007
Erbitux meets Ph III NSCLC trial endpoints
17 September 2007
Stimuvax achieves impressive 3-year survival in NSCLC
17 September 2007
NJ hIgh court denies Vioxx class action
17 September 2007
World Conference on Lung Cancer highlights important developments
17 September 2007
Crucell out-licenses vacc technology to Merck & Co
17 September 2007
Merck & Co to surpass Pfizer in cholesterol-lowering market
17 September 2007
Isentress gets ADAC's unanimous backing
17 September 2007
Swiss firm Nitec prepares for Lodotra launch, appointing CEO and CFO
10 September 2007
European cardiologists welcome lower cholesterol targets
10 September 2007
Newron opens Swiss R&D center in Basel
10 September 2007
Merck KGaA seeks EU OK for Erbitux in mCRC
10 September 2007
Merck's Cordaptive has positive impact on key lipid parameters
10 September 2007
German drug sales set to decline, VFA warns
3 September 2007
Merck Serono's matuzumab misses Ph II mCRC endpoint; future doubts
3 September 2007
UK parallel traders claim L30M Cozaar/Hyzaar savings for NHS
3 September 2007
Merck & Co opens Asia-Pacific HQ in Singapore
3 September 2007
CORRECTION: German drug sales set to decline
3 September 2007
Genmab's 1st-half loss falls 54% on sales hike
3 September 2007
Newron's safinamide misses Ph III efficacy endpoint
3 September 2007
Global CV drug market to hit $116B by 2010
3 September 2007
Strong Ph III study data for BioMarin's PKU drug
20 August 2007
Chi-Med's 1st-half net loss widens to $5.6M
20 August 2007
Merck & Co/Neuromed abandon Ph II painkiller
20 August 2007
UK Merial staff quizzed over foot and mouth outbreak
13 August 2007
Genmab regains HuMax-TAC rights
13 August 2007
Immunization campaign launched by US CDC
13 August 2007
Mylan's 1st-qtr FY 2006 income up 5% on sales
6 August 2007
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
